Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (545)	2/23/1998 7:45:00 PM
From: Bruce Russell	Read Replies (1) \| Respond to of 1580

Merck has great lawyers, Monsanto's press release on their suit is not the last word.

To: LTK007 who wrote (545)	2/23/1998 8:58:00 PM
From: Brian Malloy	Read Replies (1) \| Respond to of 1580

If you listen to Searle they may claim to be the first to patent Cox-2 and imply that they have locked the market. Merck would not agree with this assesment, and most people that follow the pharmacetical companies are probably chuckling. Cox-2 will be a new class of drugs, specific cyclo-oxygenase inhibitors. Just as there are many types of antivirals and NSAID's and so forth and so on, there will eventually be many Cox-2 drugs. Lastly, the FDA has not approved anything yet. While it appears that Searle's drug will beat Merck's to market by a few months - anything can happen - Merck could be the first to market.